CN115252627B - 一种石胆酸的用途 - Google Patents

一种石胆酸的用途 Download PDF

Info

Publication number
CN115252627B
CN115252627B CN202210966875.1A CN202210966875A CN115252627B CN 115252627 B CN115252627 B CN 115252627B CN 202210966875 A CN202210966875 A CN 202210966875A CN 115252627 B CN115252627 B CN 115252627B
Authority
CN
China
Prior art keywords
lithocholic acid
streptococcus mitis
application
test
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210966875.1A
Other languages
English (en)
Other versions
CN115252627A (zh
Inventor
郭爱疆
王帅
王玉桂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanzhou Veterinary Research Institute of CAAS
Original Assignee
Lanzhou Veterinary Research Institute of CAAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanzhou Veterinary Research Institute of CAAS filed Critical Lanzhou Veterinary Research Institute of CAAS
Priority to CN202210966875.1A priority Critical patent/CN115252627B/zh
Publication of CN115252627A publication Critical patent/CN115252627A/zh
Application granted granted Critical
Publication of CN115252627B publication Critical patent/CN115252627B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明公开一种已知化合物石胆酸的用途，即石胆酸在制备抑制缓症链球菌药物中的应用。本发明实验表明，石胆酸对缓症链球菌有良好的抗菌活性，是一种潜在的可代替现有抗生素抑制缓症链球菌的药物。

Description

一种石胆酸的用途
技术领域
本发明涉及一种已知化合物―石胆酸的用途。
背景技术
石胆酸是肠道中最重要的次级胆汁酸之一，石胆酸分子式：C24H40O3，结构：
胆汁酸是胆汁里的一个有效成分，是参与胆汁消化功能的重要成分之一，其含量变化在肝脏病诊断中具有重要的参考价值。此外有文献披露，石胆酸还具有抑制肿瘤的效果。
中国发明专利申请202111019726.6公开了石胆酸类化合物具有抗金葡菌生物被膜生长作用，对金葡菌MRSA和MSSA具有抑菌活性。
发明内容
本发明提供一种石胆酸的用途，即石胆酸在制备抑制缓症链球菌药物中的应用。
缓症链球菌属于α-溶血性链球菌(亦称甲型溶血性链球菌)，通常是人体口腔、消化道、生殖道等部位的正常菌群之一，该菌是一种条件致病菌，可致中毒性休克综合征，亚急性心内膜炎，前列腺炎等，此外，还可致肺炎、心包炎、腹膜炎、唾腺炎、口面部感染、牙源性感染、中耳炎、鼻窦炎等。据报道在发病猪体内可分离到此病原菌，并且导致仔猪发病和死亡严重，说明缓症链球菌对猪也是有致病性。在儿科常用抗生素中，缓症链球菌对氨曲南、头孢曲松、哌拉西林/他唑巴坦、阿莫西林/克拉维酸钾均有不同程度耐药，耐药率达到42.3％-48.1％。这些抗生素目前仍然是儿童肺炎的常用药物。细菌耐药是全球问题，但相应的抗生素的开发则进展缓慢，形式非常严峻，因此迫切需要一种新的抗菌药物或抗菌产品来抑制细菌。
本发明实验表明，石胆酸对缓症链球菌有良好的抗菌活性，是一种潜在的可代替现有抗生素抑制缓症链球菌的药物。
附图说明
图1：石胆酸浓度与缓症链球菌生长抑制率关系图。
图2：氯霉素浓度与缓症链球菌生长抑制率关系图.
具体实施方式
以下结合本发明的相关实验进行解说。下述本发明实验中采用微量肉汤二倍稀释法对石胆酸进行了体外抗菌活性测试，考察其对缓症链球菌的抗菌活性，并与阳性对照氯霉素进行比较。
1.供试品及对照
1.1供试品
名称：石胆酸，采用市售产品
供试品临用前用乙醇配制成最大浓度20mg/mL，依次对倍稀释。
1.2对照品
名称：氯霉素，市售品。
2.测试菌株及其培养方法
2.1菌株：缓症链球菌ATCC49456
2.2菌种来源：购于北京百欧博伟生物技术有限公司。
2.3培养条件：Todd-Hewitt Broth，37℃孵育24h-48h。
2.4菌种开启接种并培养
用75％酒精棉擦拭西林瓶外部，在安全柜内使用尖嘴钳去除塑料盖及铝盖。缓慢开启胶塞，用75％酒精棉消毒瓶口部分，使用无菌吸管注入0.5ml液体培养基复溶冻干粉末，将悬液接种在培养基上，37℃培养24小时后，挑取单个菌落于液体培养基中在相同的培养条件下培养增菌。
2.5菌液工作液的准备
当OD600值达到0.5左右(约108CFU/ml)，经THB肉汤梯度稀释(0、10、100、1000、10000、100000、10000倍)后，取100μL菌悬液接种于固体培养基上，培养24h后计数活菌数，计算菌悬液浓度，再将此混悬菌液进行稀释，使菌悬液最终浓度约为2×106CFU/ml。菌种操作均在无菌条件下进行，实验完毕，所有耗材经灭菌再做丢弃处理。
3.最低抑菌浓度的测定
3.1测试方法：采取微量肉汤稀释法，进行最低抑菌浓度(minimum inhibitoryconcentration，MIC)的测定。
实验分为阳性对照组(即不含药物的菌悬液)、阴性对照组(含溶媒乙醇的培养基)和实验组(含不同浓度的石胆酸菌悬液)。以上各组均设置3个平行组。将浓度为100μg/ml的石胆酸实验液按对倍稀释溶于液体培养基中，使其终浓度为100μg/ml、50μg/ml、25μg/ml、12.5μg/ml、6.25μg/ml、3.125μg/ml、0μg/ml。浓度为2×106CFU·mL-1菌悬液与各组药液按比例1∶1各100μL，分别接种于无菌96孔板中，使菌悬液的终浓度为1×106CFU/ml，置于适当的培养条件下培养20h。同时设置对照品氯霉素，使其终浓度分别为32μg/ml、16μg/ml、8μg/ml、4μg/ml、2μg/ml、1μg/ml、0μg/ml。培养结束后，在黑色背景下进行肉眼观察，平皿内未见细菌生长的最低药物浓度即为石胆酸的最低抑菌浓度(MIC)。所有菌种的MIC测定实验重复3次。悬浮菌体测OD600值，不同浓度的供试品及对照抑菌率的计算方法：抑菌率(％)＝1-(供试品OD值—阴性对照OD值)/(阳性对照OD值—阴性对照OD值)×100％。通过曲线拟合得函数计算而得MIC50，MIC50指能抑制50％受试菌所需最低抑菌浓度(MIC)。
3.2结果判断
本次试验结果见表1，抑制率图见图1。当阳性对照孔(即不含药物)内细菌明显生长，试验才有意义。结果显示，阳性对照孔(即不含药物)内细菌正常生长，溶媒对照培养基孔无菌生长。对照品氯霉素对缓症链球菌的MIC值为4μg/ml，参见表2和图2，符合美国临床实验室标准化委员会(National committee for clinical library standardization,NCCLS)2001年的《抗微生物药物敏感试验的执行标准：第十一版信息增刊》M100-S11中氯霉素对缓症链球菌≤4μg/ml的标准，说明本实验方法是可靠的。
统计结果表明：石胆酸对受试的缓症链球菌的MIC50为11.06μg/ml。综上所述，石胆酸有良好的抑制缓症链球菌活性。
表1:不同浓度石胆酸对缓症链球菌生长影响的吸光值测定
表2：不同浓度氯霉素对缓症链球菌生长影响的吸光值测定

Claims (1)

1.石胆酸在制备抑制缓症链球菌ATCC49456生长的药物中的应用。
CN202210966875.1A 2022-08-11 2022-08-11 一种石胆酸的用途 Active CN115252627B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210966875.1A CN115252627B (zh) 2022-08-11 2022-08-11 一种石胆酸的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210966875.1A CN115252627B (zh) 2022-08-11 2022-08-11 一种石胆酸的用途

Publications (2)

Publication Number Publication Date
CN115252627A CN115252627A (zh) 2022-11-01
CN115252627B true CN115252627B (zh) 2023-10-10

Family

ID=83750465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210966875.1A Active CN115252627B (zh) 2022-08-11 2022-08-11 一种石胆酸的用途

Country Status (1)

Country Link
CN (1) CN115252627B (zh)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077123B2 (en) * 2016-02-29 2021-08-03 Tel Hashomer Medical Research Infrastructure And Services Ltd. Use of bile acids and bile salts as anti bacterial agents for inhibition of bacterial conjugation and horizontal gene transfer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Amy M. Sheflin等.Cancer-Promoting Effects of Microbial Dysbiosis.《Curr Oncol Rep》.2014,第16卷(第406期),第1-9页. *
Stephen M. Riordan等.Liver Damage in Human Small Intestinal Bacterial Overgrowth.《the american journal of gastroenterology》.1998,第93卷(第2期),第234-237页. *

Also Published As

Publication number Publication date
CN115252627A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
WO2010021930A1 (en) Prevention and treatment of mrsa infections with chitosan-derivatives
Namratha et al. Characterization and antibiogram of Klebsiella spp. isolated from clinical specimen in a rural teaching hospital
Aldons A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis
Heimdahl et al. Effect of erythromycin and clindamycin on the indigenous human anaerobic flora and new colonization of the gastrointestinal tract
Davcheva-Chakar et al. Adenoid vegetations–reservoir of bacteria for chronic otitis media with effusion and chronic rhinosinusitis
CN113491692A (zh) C-jun n末端激酶抑制剂su3327的用途
Tel et al. Investigation of the antibiotic resistance and biofilm formation of Staphylococcus aureus strains isolated from gangrenous mastitis of ewes
Crombleholme et al. Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin
CN110151752A (zh) 一种茶多酚类组合物及其在制备抗猪链球菌药物中的应用
Jalil et al. Inhibitory activity of Mentha spicata oils on biofilms of Proteus mirabilis isolated from burns
CN115252627B (zh) 一种石胆酸的用途
FR et al. Antimicrobial and immunological studies on Pasteurella multocida and Mannheimia haemolytica recovered from calves affected with respiratory manifestations
CN115350198B (zh) 一种表别石胆酸的用途
CN115381841B (zh) 一种异石胆酸的用途
Ngu Ngwa et al. Bacterial pathogens involved in bovine mastitis and their antibiotic resistance patterns in the Adamawa region of Cameroon
CN115531394B (zh) 脱氧胆酸在制备抗缓症链球菌的产品中的应用
CN115364107B (zh) 石胆酸的用途
Tareq et al. An application of bacteriocin-producing vaginal Lactobacillus Crispatus IS30 in a gel formula against some vaginal pathogens
CN115569141B (zh) 脱氧胆酸在制备抗口腔链球菌产品中的应用
CN115531395B (zh) 脱氧胆酸在制备抗婴儿链球菌的产品中的应用
CN112353820B (zh) 新型st型crpa菌株的应用
Martens et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of post-cesarean section endometritis
de Vries-Hospers et al. Influence of quinolones on throat-and faecal flora of healthy volunteers
CN117398393A (zh) 12-酮基石胆酸在制备抗缓症链球菌产品中的应用
Salih et al. Anti–biotypes of Different Bacteria Isolated from Different Clinical Sources

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant